Schedule 13G ownership disclosure

BIODEXA PHARMACEUTICALS PLC ADR

Ordinary Shares, nominal value 0.000001 GBP per share · CUSIP: 59564R880

Event date: 2025-06-30

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Cavalry Fund I LP

    Shares: 0.00 · Class: 0%

  • C/M CAPITAL PARTNERS, LP

    Shares: 0.00 · Class: 0%

  • Cavalry Investment Fund, LP

    Shares: 0.00 · Class: 0%

  • Cavalry Fund I Management LLC

    Shares: 0.00 · Class: 0%

  • Mercer Street Global Opportunity Fund, LLC

    Shares: 0.00 · Class: 0%

  • Mercer Street Capital Partners, LLC

    Shares: 0.00 · Class: 0%

  • Thomas Walsh

    Shares: 0.00 · Class: 0%

  • Jonathan Juchno

    Shares: 0.00 · Class: 0%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000902664-25-005038
Form type
SCHEDULE 13G/A
Filer
Biodexa Pharmaceuticals Plc
CIK
CIK 1643918
Filed
Nov 14, 2025
Reporting period
Jun 30, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub